US 11,944,607 B2
Treatment of progressive neurodegenerative disease with ibudilast
Michael E. Kalafer, San Diego, CA (US); Kenneth W. Locke, Carlsbad, CA (US); Kazuko Matsuda, Beverly Hills, CA (US); and Richard E. Gammans, Edmond, OK (US)
Assigned to MediciNova, Inc., La Jolla, CA (US)
Filed by MediciNova, Inc., La Jolla, CA (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,563.
Application 17/366,563 is a continuation of application No. 16/400,844, filed on May 1, 2019, granted, now 11,083,713.
Application 16/400,844 is a continuation of application No. 15/078,291, filed on Mar. 23, 2016, abandoned.
Application 15/078,291 is a continuation of application No. 14/188,061, filed on Feb. 24, 2014, granted, now 9,314,452.
Application 14/188,061 is a continuation of application No. 13/725,627, filed on Dec. 21, 2012, granted, now 9,114,136.
Application 13/725,627 is a continuation of application No. 13/402,702, filed on Feb. 22, 2012, granted, now 8,338,453.
Application 13/402,702 is a continuation of application No. 12/169,042, filed on Jul. 8, 2008, granted, now 8,138,201.
Claims priority of provisional application 61/042,181, filed on Apr. 3, 2008.
Claims priority of provisional application 60/929,745, filed on Jul. 11, 2007.
Prior Publication US 2022/0168283 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 45/06 (2013.01)] 17 Claims
 
1. A method of reducing the likelihood of disability progression in a patient diagnosed with a progressive form of multiple sclerosis, the method comprising administering to the patient in need thereof a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof.